Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Adib E, Nassar AH, Akl EW, Alaiwi SA, Nuzzo PV, Mouhieddine TH, et al. CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clin Cancer Res. 2021;27(14):4025-4035.

Zanettini C, Omar M, Dinalankara W, Imada EL, Colantuoni E, Parmigiani G, et al. Influenza Vaccination and COVID-19 Mortality in the USA: An Ecological Study. Vaccines (Basel). 2021;9(5).

Pappa T, Ahmadi S, Marqusee E, Johnson HL, Nehs MA, Cho NL, et al. Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAFV600E -Driven Papillary Thyroid Cancer Patients. Clin Cancer Res. 2021;27(15):4256-4264.

Boyraz B, Sadow PM, Asa SL, Dias-Santagata D, Nose V, Mete O. Cribriform-Morular Thyroid Carcinoma Is a Distinct Thyroid Malignancy of Uncertain Cytogenesis. Endocr Pathol. 2021;32(3):327-335.

Racine-Brzostek SE, Yee JK, Sukhu A, Qiu Y, Rand S, Barone PD, et al. More rapid, robust and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals. JCI Insight. 2021.

Stern ES, Siddiqui MT. Nuclear hypochromasia: Shedding light on the "lightness" of high-grade urothelial carcinoma. Diagn Cytopathol. 2021;49(9):1032-1035.

Green DB, La Rosa FG, Craig PG, Khani F, Lam ET. Metastatic Mature Teratoma and Growing Teratoma Syndrome in Patients with Testicular Non-Seminomatous Germ Cell Tumors. Korean J Radiol. 2021;22(10):1650-1657.

Linares JF, Zhang X, Martinez-Ordoñez A, Duran A, Kinoshita H, Kasashima H, et al. PKCλ/ι inhibition activates an ULK2-mediated interferon response to repress tumorigenesis. Mol Cell. 2021.

Liu D, Augello MA, Grbesa I, Prandi D, Liu Y, Shoag JE, et al. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. J Clin Invest. 2021;131(10).

Trzebucki AM, Westblade LF, Loo A, Mazur S, Jenkins SG, Calfee DP, et al. Real-world implementation and impact of a rapid carbapenemase detection test in an area endemic for carbapenem-resistant Enterobacterales. Infect Control Hosp Epidemiol. 2021:1-4.